"FDA Expands CRISPR Gene-Editing Approval for Beta Thalassemia and Second Disease"
TL;DR Summary
The FDA has expanded its approval of the CRISPR-based medicine Casgevy to include the treatment of beta thalassemia, an inherited blood disorder, following its initial approval for sickle cell disease in December. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, the therapy's expanded approval comes ahead of the FDA's decision deadline and is seen as a promising development for patients with thalassemia.
- CRISPR-based therapy receives expanded approval for beta thalassemia STAT
- FDA clears first CRISPR treatment for a second disease, beta thalassemia CNN
- CRSP Stock Dips Despite Snagging A Second Gene-Editing OK; VRTX Stock Continues On Its Warpath Investor's Business Daily
- Vertex, Crispr Get Second FDA Approval for Gene Therapy Bloomberg
- FDA Approves New CRISPR Gene-Editing Treatment Forbes
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
56%
140 → 61 words
Want the full story? Read the original article
Read on STAT